Bandi Linea B

AOR-MA

Aorticlab – FLOWer Market Analysis
Digital care innovation
Spoke5_AOR-MAimage
Scheda del progetto
Data
Start date
Valore
Total value
€ 67.500,00
Durata
Duration
12 months
Investimento
Investment nodes
€ 33.750,00

Aorticlab, an innovative SME in the field of cardiovascular devices, aims to improve patient safety by offering advanced and affordable clinical solutions. It is developing two innovative products, FLOWer and Gemini, to treat severe aortic stenosis. FOCUS on obtaining CE certification for the launch of FLOWer requires in-depth analysis of the international market to assess its profitability through qualitative and quantitative sizing and segmentation, including comparison with competitors, the positioning, and pricing. A Go-to-Market strategy will be developed and optimized, integrating the analysis of key opinion leaders and improving the Marketing&Sales plan for the launch of Q4 2024.

 

 

Contact:

Franco Osta 

franco.osta@aorticlab.ch

The goal
Document

Aorticlab is developing FLOWer, an anti-embolic filter for TAVI, aiming to protect patients from embolic injuries. The market analysis service supports the product launch by providing insights into the TAVI market, competitive analysis, positioning, and pricing. The goal is to optimize the Go-to-Market strategy, enhance product positioning, and expand market entry opportunities, supporting preventive medicine and patient safety objectives.

Why is it innovative
Document

Aorticlab's market analysis is innovative because it uses digital tools to access large volumes of data, enabling a detailed and comprehensive examination of the target market. This digital approach reduces time, costs, and environmental impact. Additionally, it provides competitive advantages such as adapting the strategic plan, identifying obstacles and opportunities, comparing with competing products, and engaging industry opinion leaders to optimize the marketing strategy.

Impact on the users
Document

The market analysis will have a significant impact on Aorticlab, allowing it to reduce market entry risk, develop targeted products, identify emerging factors, and improve competition comparison. This will optimize the product launch strategy, facilitate international expansion, and enhance the safety of surgical procedures for patients, contributing to improved life expectancy and promoting preventive medicine.